Raymond James Financial
GILD icon

Raymond James Financial’s Gilead Sciences GILD Stock Holding History

Raymond James Financial’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355M Sell
2,561,652
-173,265
-6% -$24.3M 0.11% 159
2025
Q4 		$336M Buy
2,734,917
+919,106
+51% +$112M 0.1% 164
2025
Q3 		$202M Buy
1,815,811
+51,188
+3% +$5.82M 0.06% 270
2025
Q2 		$196M Sell
1,764,623
-271,484
-13% -$28.9M 0.07% 262
2025
Q1 		$228M Sell
2,036,107
-208,563
-9% -$21.5M 0.09% 216
2024
Q4 		$207M Buy
+2,244,670
New +$202M 0.08% 226

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Raymond James Financial's GILD Position: Q1 2026 in Review

Raymond James Financial reduced its Gilead Sciences (GILD) stake by 6.3% in Q1 2026, selling an estimated $24.3M and leaving 2,561,652 shares worth $355M. The position accounts for 0.11% of the portfolio, ranked #159.

Raymond James Financial first reported a position in GILD in Q4 2024 and has held it in 6 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Raymond James Financial held 2,561,652 shares of Gilead Sciences worth $355M as of Q1 2026.
  • Raymond James Financial sold 173,265 Gilead Sciences shares in Q1 2026, an estimated $24.3M.
  • Gilead Sciences made up 0.11% of Raymond James Financial's portfolio in Q1 2026, its #159 holding.
  • Raymond James Financial first reported a position in Gilead Sciences in Q4 2024 and has held it in 6 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.